ReviewFrontiers in immunology2022
Ang2-Targeted Combination Therapy for Cancer Treatment.
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Preoperative nutritional status as a predictor of postoperative overall survival in abdominal tumor surgery: a systematic review and meta-analysis.Frontiers in surgery · 2025Pooled it
- Systemic Molecular Network Alterations Associated with FoxA2 in Gastric Cancer.International journal of molecular sciences · 2026Article
- Self-Adaptive Charge Transfer States in Aqueous Solutions Promote Fast Intersystem Crossing in a Photosensitizer for Tumor Inhibition.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Refining Vascular Biomarker-Guided Risk Stratification for Cancer Therapy-Related Cardiac Dysfunction.JACC. CardioOncology · 2026Article
- TIE2-positive cells in the nucleus pulposus with a purpose: the who, what and why.Journal of biomedical science · 2026Review
- Tumor immune-vascular crosstalk: synergy and translation of immune checkpoint inhibitors and anti-angiogenic agents in melanoma.Frontiers in immunology · 2026Review
- Article
- Article
- Correlations between primary tumour location, biomarkers of inflammation and lung injury, and postoperative pulmonary complications in patients underwent laparoscopic colorectomy: a propensity score matched analysis of 300 patients.Frontiers in immunology · 2025Article
- Advances in nanomedicine and delivery systems for gastric cancer research.Frontiers in bioengineering and biotechnology · 2025Review
- Potential Role of the Tie2/ Angiopoietin System in Hepatitis C Virus- Induced Hepatocellular Carcinoma.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Microfluidic-SERS sensing system based on dual signal amplification and aptamer for gastric cancer detection.Mikrochimica acta · 2024Article
- The Antitumour Mechanisms of Carotenoids: A Comprehensive Review.Antioxidants (Basel, Switzerland) · 2024Review
- The Impact of Liver Steatosis on Interleukin and Growth Factors Kinetics during Chronic Hepatitis C Treatment.Journal of clinical medicine · 2024Article
- DCE-MRI-based radiomics in predicting angiopoietin-2 expression in hepatocellular carcinoma.Abdominal radiology (New York) · 2023Article
- Targeting vascular normalization: a promising strategy to improve immune-vascular crosstalk in cancer immunotherapy.Frontiers in immunology · 2023Review
- Identification of the hub genes associated with prostate cancer tumorigenesis.Frontiers in oncology · 2023Article
- The Role of Stem Cell Factor, Epidermal Growth Factor and Angiopoietin-2 in HBV, HCV, HCC and NAFLD.Life (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Angiopoietin-2 (Ang2), a member of the angiopoietin family, is widely involved in the process of vascular physiology, bone physiology, adipose tissue physiology and the occurrence and development of inflammation, cardiac hypertrophy, rheumatoid, tumor and other diseases under pathological conditions. Proliferation and metastasis of cancer largely depend on angiogenesis. Therefore, anti-angiogenesis has become the target of tumor therapy. Due to the Ang2 plays a key role in promoting angiogenesis and stability in vascular physiology, the imbalance of its expression is an important condition for the occurrence and development of cancer. It has been proved that blocking Ang2 can inhibit the growth, invasion and metastasis of cancer cells. In recent years, research has been constantly supplemented. We focus on the mechanisms that regulate the expression of Ang2 mRNA and protein levels in different cancers, contributing to a better understanding of how Ang2 exerts different effects in different cancers and stages, as well as facilitating more specific targeting of relevant molecules in cancer therapy. At the same time, the importance of Ang2 in cancer growth, metastasis, prognosis and combination therapy is pointed out. And finally, we will discuss the current investigations and future challenges of combining Ang2 inhibition with chemotherapy, immunotherapy, and radiotherapy to increase its efficacy in cancer patients. This review provides a theoretical reference for the development of new targets and effective combination therapy strategies for cancer treatment in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.